Advanced searches left 3/3

Organ Transplantation - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 19 April 2022

* If you want to update the article please login/register

The Organ Transplant Recipient HPV and Skin Cancer Study

The aim of this study, according to immunocompetent controls, was to investigate the general and type-specific prevalence, incidence, and persistence of cervical HPV infection in OTRs. Compared to immunocompetent controls, researchers are looking at the overall and type-specific prevalence of oral HPV infection in female OTRs. In female OTRs, the presence of cervical and oral HPV infection was due to a combination of lifestyle and medical causes. To determine the role of lifestyle, medical, and organ transplantation-related causes for OTRs' prevalence and incidence of skin dysplasia. In OTRs, the researchers will investigate the links between skin dysplasia and the incidence of cervical HPV infection and VZV infection. OTRs will obtain the following data: At baseline: OTRs will collect questionnaire, dermatological skin examination, diagnosis of skin photodamage, medical record analysis, cervico-vaginal HPV self-sample test, oral sample for future study, and blood samples for vitamin D testing. After 6 months: A new blood sample for vitamin D testing was obtained after 6 months. Female immunocompetent controls will perform the following samples: questionnaire, cervico-vaginal HPV self-sample test, and oral sample for HPV testing. Since 12 months: New cervico-vaginal HPV self-sample test has been repeated. From these databases, there will be information on precancerous lesions and cancer; other HPV-related diseases; HPV vaccination and cervical cancer screening; socio-demographic characteristics; and emigration and death of women in the study population will be determined.

Source link: https://clinicaltrials.gov/ct2/show/NCT05284877


Seroprevalence of Hepatitis E in The Organ Transplant Subjects

Hepatitis E virus infection commonly occurs in the developing world as an acute self-limiting hepatitis. However, there have been reports that chronic hepatitis E could arise in immunocompromised patients such as renal and liver transplant recipients, as well as transplant recipients. In patients with chronic hepatitis E infection, cirrhosis has also been identified. Immunosuppression post-organ transplantation predisposes people to an elevated risk of hepatitis E infection, according to We hypothesize. We therefore want to determine the seropreval of antibody to hepatitis E IgG in organ transplant recipients and compare it to patients with organ transplant waitlists. The NIH will conduct a short questionnaire to determine risk factors for the onset of hepatitis E.

Source link: https://clinicaltrials.gov/ct2/show/NCT02190253


Viral Specific T-cells (VSTs) for Treatment of Viral Infections After Solid Organ Transplant

The aim of this research is to learn more about the use of viral specific T-lymphocytes to treat viral infections that may occur following solid organ transplantation. VSTs are cells that have been specially developed to fight viral infections that may arise following a solid organ transplant. Immunosuppression reduction may place the organ in danger of rejection. In this review, the investigators are looking for a safer way to treat these infections and minimize complications. Other side effects such as damage to the kidneys or decrease in blood count can also play a role, so the investigators are looking for a more effective way to prevent these infections and minimize complications.

Source link: https://clinicaltrials.gov/ct2/show/NCT04331275


Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

Instillation of stool from a healthy donor into a CDI patient's intestine is a new technique that has recently gained attention. This treatment, Fecal Microbiota Transplantation, has been shown to reduce CDI recurrence in non-comparative studies by more than 95%, but SOT recipients are a special population study population due to profound immunosuppression, frequent antibiotic use, and regular exposure to CDI, which all of which have repeatedly and persistently affect the gut microbiome. This significant field gap in the field must be addressed by a trial of FMT in SOT recipients with CDI.

Source link: https://clinicaltrials.gov/ct2/show/NCT03617445


Calcipotriol Plus 5-Fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients

The primary aim of this investigator-initiated clinical trial is to determine the effectiveness of topical calcipotriol treated with 5-fluorouracil treatment in OTRs of immunosuppressive drugs with precancerous skin lesions such as actinic keratoses and a history of non-melanoma skin cancer in order to eliminate AKs and prevent squamous cell carcinoma formation. In combination with 5-FU, we have established the safety of calcipotriol in infants with immune deficiencies against AKs. We will investigate whether this efficacy is maintained in OTRs on immunocompetent patients after transplantation, based on our prior results showing the synergistic effect of TSLP induction by calcipotriol, as well as the cytotoxic effects of 5-FU that promotes a robust T cell immune response against early skin cancer in immunocompetent patients.

Source link: https://clinicaltrials.gov/ct2/show/NCT04642287


Calcipotriol Plus 5-Flourouracil Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

The primary aim of this investigator-initiated clinical trial is to determine the safety of topical calcipotriol and 5-flourourouracil therapy in organ transplant patients with precancerous skin lesions and a history of skin cancer in order to avoid squamous cell carcinoma formation after transplantation. Previously, we have reported the high success of topical calcipotriol plus 5-FU immunotherapy for AKs on the face and scalp, significantly reducing the chance of SCC disease in immunocompetent patients within 3 years post-treatment. The induction of strong T cell immunity and TRM cell formation against AKs was the catalyst for this SCC risk reduction. Our latest research shows the synergistic effects of calcipotriol, when used with 5-FU in combination with 5-FU on a robust T cell immune response against early skin cancer in immunocompetent patients.

Source link: https://clinicaltrials.gov/ct2/show/NCT04329221

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions